Skip to content
naulon

Not checkedNot checked for notices yet.

Lupus-Like Glomerulonephritis Associated With Regorafenib, a Multikinase Inhibitor

Anna Strasma, Howard Coke, Omar Mamlouk and 2 more

Kidney Medicine · 2021

doi:10.1016/j.xkme.2020.11.011 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Drug-induced lupus glomerular diseases have historically been associated with hydralazine, but new drugs that modify the growth, metabolism, and immunity of cells are increasingly found to cause glomerular disease. This includes anti–tumor necrotic factor and other antibody agents used in cancer treatment. Multitarget tyrosine kinases such as regorafenib are increasingly used in metastatic malignancies with good outcomes. Currently, they are not known to have kidney complications except for proteinuria, hypertension, and electrolyte disturbances such as hypophosphatemia. We report a patient who presented within months after starting regorafenib therapy for metastatic colon cancer with acute kidney injury, proteinuria, and hematuria. Biopsy revealed endocapillary proliferative glomerulonephritis with full-house staining on immunofluorescence in the absence of any systemic manifestation of systemic lupus erythematosus. The kidney injury improved with corticosteroid treatment and discontinuation of regorafenib therapy. We discuss the possible mechanisms that led to this class IV pattern of lupus nephritis and conclude that it is likely drug-induced lupus nephritis from regorafenib.

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.